XML 47 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment reporting
12 Months Ended
Dec. 31, 2021
Segment reporting  
Segment reporting

23     Segment reporting

The Company’s operations are categorized into one industry segment, which is medical technology focused on magnetic resonance guided ablation procedures for the treatments to ablate the prostate gland, uterine fibroids, osteoid osteoma and nerves for palliative pain relief for patients with metastatic bone disease. The Company is managed geographically in Canada, Germany, USA, China and Finland.

For the year ended December 31, 2021:

    

Canada

    

USA

    

Germany

    

Total

$

$

$

$

Revenue

 

  

 

  

Capital equipment

 

1,724

1,426

 

3,150

Recurring - non-capital

 

353

2,090

1,280

 

3,723

2,077

2,090

2,706

6,873

For the year ended December 31, 2020:

    

Canada

    

Germany

    

Total

$

$

$

Revenue

 

Capital equipment

 

4,031

550

4,581

Recurring - non-capital

 

2,454

269

2,723

 

6,485

819

7,304

Other financial information by segment as at December 31, 2021:

    

Canada

    

USA

    

Germany

    

China

    

Finland

    

Total

$

$

$

$

$

$

Total assets

 

81,529

2,068

1,445

81

1,652

86,775

Goodwill and intangible assets

 

4,124

4,124

Property and equipment

 

490

298

788

Right-of-use assets

1,106

10

1,116

Amortization of intangible assets

 

1,029

1,029

Depreciation of property and equipment

408

110

518

Depreciation of right-of-use assets

 

234

8

90

332

Other financial information by segment as at December 31, 2020:

    

Canada

    

USA

    

Germany

    

Finland

    

Total

$

$

$

$

$

Total assets

 

98,890

456

 

1,682

 

3,573

 

104,601

Goodwill and intangible assets

 

4,576

 

 

 

4,576

Property and equipment

 

859

 

 

 

859

Right-of-use assets

 

1,325

 

 

99

 

1,424

Amortization of intangible assets

 

881

 

 

 

881

Depreciation of property and equipment

 

236

 

 

116

 

352

Depreciation of right-of-use assets

 

212

 

 

93

 

305